AnorMED is to discontinue the development of its chemokine inhibitorAMD-3100 in HIV due to abnormal cardiac activity seen in two patients receiving the drug in clinical trials. In addition, AMD-3100 did not meet the criteria for efficacy at the doses evaluated in the study. Michael Abrams, chief executive of AnorMED, said the firm was disappointed with the discontinuation as AMD-3100 was its lead product within its chemokine inhibitor program, although other candidates are further back in development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze